Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $(0.16) by 268.75 percent. This is a 550 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $29.612 million which beat the analyst consensus estimate of $28.142 million by 5.22 percent. This is a 13.16 percent increase over sales of $26.168 million the same period last year.